Front. Pharmacol.

Frontiers in Pharmacology

Front. Pharmacol.

1663-9812

Frontiers Media S.A.

10.3389/fphar.2017.00427

Pharmacology

General Commentary

Expression of Concern: Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze

Frontiers Editorial Office ^*

Edited and reviewed by: Théophile Godfraind, Université Catholique de Louvain, Belgium

*Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

28 06 2017

2017

427

14 06 2017 14 06 2017

2017

Frontiers Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

An expression of concern on Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze by Roy, K., Cheung, C. H. A., Kanwar, R. K., Sandhir, R., and Kanwar, J. R. (2017). Front. Pharmacol. 8:223. doi: 10.3389/fphar.2017.00223

With this notice, Frontiers states its awareness of serious allegations surrounding the article “Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze” published on 5 May 2017. Our Chief Editors will direct an investigation in full accordance with our procedures. The situation will be updated as soon as the investigation is complete.